Financial results for the period ended September 30, 2026
As filed · Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. The Unaudited Standalone and Consolidated Financial Results for the quarter and half. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedGlenmark expects to launch some of its respiratory products from H1 FY26 onwards.
Glenmark completed the successful launches of 13 new products during fiscal year 2025, consisting of a mix of immediate-release oral solids, a semi-solid ointment, several injectables and an oral contraceptive.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- However, the Company expects an uptick in the business from FY26 onwards on the back of potential launches in (management committed by FY26)
- Glenmark expects to launch some of its respiratory products from H1 FY26 onwards. (management committed by H1 FY26)
Evidence
- Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%